X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs LUPIN LTD - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD LUPIN LTD BIOCON LTD/
LUPIN LTD
 
P/E (TTM) x 82.9 19.9 416.3% View Chart
P/BV x 7.8 2.7 289.1% View Chart
Dividend Yield % 0.2 0.9 17.1%  

Financials

 BIOCON LTD   LUPIN LTD
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
LUPIN LTD
Mar-17
BIOCON LTD/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,1621,750 66.4%   
Low Rs4831,384 34.9%   
Sales per share (Unadj.) Rs194.6387.4 50.2%  
Earnings per share (Unadj.) Rs34.456.6 60.8%  
Cash flow per share (Unadj.) Rs48.376.8 62.8%  
Dividends per share (Unadj.) Rs1.007.50 13.3%  
Dividend yield (eoy) %0.10.5 25.4%  
Book value per share (Unadj.) Rs241.9298.9 80.9%  
Shares outstanding (eoy) m200.00451.58 44.3%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x4.24.0 104.5%   
Avg P/E ratio x23.927.7 86.4%  
P/CF ratio (eoy) x17.020.4 83.5%  
Price / Book Value ratio x3.45.2 64.8%  
Dividend payout %2.913.2 21.9%   
Avg Mkt Cap Rs m164,440707,513 23.2%   
No. of employees `0009.216.8 55.0%   
Total wages/salary Rs m7,47028,495 26.2%   
Avg. sales/employee Rs Th4,213.910,418.3 40.4%   
Avg. wages/employee Rs Th809.01,697.0 47.7%   
Avg. net profit/employee Rs Th745.21,523.0 48.9%   
INCOME DATA
Net Sales Rs m38,911174,943 22.2%  
Other income Rs m1,5711,065 147.5%   
Total revenues Rs m40,482176,008 23.0%   
Gross profit Rs m9,79544,931 21.8%  
Depreciation Rs m2,7729,122 30.4%   
Interest Rs m2601,525 17.0%   
Profit before tax Rs m8,33435,349 23.6%   
Minority Interest Rs m163-72 -227.3%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6169,785 16.5%   
Profit after tax Rs m6,88125,575 26.9%  
Gross profit margin %25.225.7 98.0%  
Effective tax rate %19.427.7 70.0%   
Net profit margin %17.714.6 121.0%  
BALANCE SHEET DATA
Current assets Rs m40,477119,542 33.9%   
Current liabilities Rs m16,78361,206 27.4%   
Net working cap to sales %60.933.3 182.6%  
Current ratio x2.42.0 123.5%  
Inventory Days Days6076 78.4%  
Debtors Days Days8390 92.2%  
Net fixed assets Rs m45,073131,660 34.2%   
Share capital Rs m1,000903 110.7%   
"Free" reserves Rs m47,377134,073 35.3%   
Net worth Rs m48,377134,976 35.8%   
Long term debt Rs m21,08256,478 37.3%   
Total assets Rs m93,942266,073 35.3%  
Interest coverage x33.124.2 136.7%   
Debt to equity ratio x0.40.4 104.1%  
Sales to assets ratio x0.40.7 63.0%   
Return on assets %7.610.2 74.6%  
Return on equity %14.218.9 75.1%  
Return on capital %12.619.3 65.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,98881,885 15.9%   
Fx outflow Rs m7,89921,506 36.7%   
Net fx Rs m5,08960,378 8.4%   
CASH FLOW
From Operations Rs m6,40041,148 15.6%  
From Investments Rs m-4,985-25,287 19.7%  
From Financial Activity Rs m-1,7754,332 -41.0%  
Net Cashflow Rs m-47320,193 -2.3%  

Share Holding

Indian Promoters % 40.4 46.6 86.7%  
Foreign collaborators % 20.6 0.2 10,300.0%  
Indian inst/Mut Fund % 8.4 11.3 74.3%  
FIIs % 10.7 31.9 33.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.1 197.0%  
Shareholders   109,995 98,259 111.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  PFIZER  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS